Minerva Surgical

Minerva Surgical, Inc. is a medical technology company, which engages in the research, development, manufacture, and commercialization of invasive solutions for uterine healthcare needs of women. It offers therapeutic devices for abnormal uterine bleeding treatment. The company was founded by Csaba Truckai in 2008 and is headquartered in Santa Clara, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Minerva Surgical, Inc. engages in the research, development, manufacture, and commercialization of invasive solutions for uterine healthcare needs of women. It offers therapeutic devices for abnormal uterine bleeding treatment. The company was founded by Csaba Truckai in 2008 and is headquartered in Santa Clara, CA.

Minerva Surgical, Inc. (NASDAQ:UTRS ) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Caroline Corner - Investor Relations Dave Clapper - President and Chief Executive Officer Joel Jung - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Matthew O'Brien - Piper Sandler Operator Good day and thank you for standing by. Welcome to the Minerva Surgical Second Quarter 2022 Earnings Call.

Minerva Surgical, Inc. (UTRS) CEO Dave Clapper on Q2 2022 Results - Earnings Call Transcript

SANTA CLARA, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today reported second quarter financial results for the period ended June 30, 2022.

Minerva Surgical Reports Second Quarter 2022 Financial Results

Social Media Campaign and Event Series Encourage Women to Talk Openly About Their Periods Social Media Campaign and Event Series Encourage Women to Talk Openly About Their Periods

Minerva Surgical Announces Time To Talk Campaign

SANTA CLARA, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Minerva Surgical to Announce Second Quarter 2022 Financial Results

SANTA CLARA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (“Minerva Surgical” or the “Company”), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today announced that the board of directors (the “Board”) of Minerva Surgical has appointed Derrick Sung, Ph.D. to serve as a Class II director, with a term expiring at the 2023 annual meeting of stockholders or until his successor has been duly elected and qualified. The Board has affirmatively determined that Dr. Sung is an independent director pursuant to the listing standards of The NASDAQ Stock Market.

Minerva Surgical Announces Appointment of Derrick Sung, Ph.D. to Board of Directors

Minerva Surgical, Inc. (NASDAQ:UTRS ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Caroline Corner - Investor Relations David Clapper - President and Chief Executive Officer Joel Jung - Chief Financial Officer Conference Call Participants Danielle Antalffy - SVB Securities Operator Good day, and thank you for standing by. Welcome to the Minerva Surgical First Quarter 2022 Earnings Call.

Minerva Surgical, Inc. (UTRS) CEO David Clapper on Q1 2022 Results - Earnings Call Transcript

SANTA CLARA, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today reported first quarter financial results for the period ended March 31, 2022.

Minerva Surgical Reports First Quarter 2022 Financial Results

SANTA CLARA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the following investor conferences:

Minerva Surgical to Present at Upcoming Investor Conferences

SANTA CLARA, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its first quarter 2022 financial results on Wednesday, May 11, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Minerva Surgical to Announce First Quarter 2022 Financial Results

Minerva calls on women to talk about their periods Minerva calls on women to talk about their periods

Minerva Surgical Announces AUB Awareness Day

SANTA CLARA, Calif., March 08, 2022 (GLOBE NEWSWIRE) --  Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today reported fourth quarter and full-year financial results for the period ended December 31, 2021.

Minerva Surgical Reports Fourth Quarter and Full-Year 2021 Financial Results

SANTA CLARA, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its fourth quarter and full-year 2021 financial results on Tuesday, March 8, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Minerva Surgical to Announce Fourth Quarter and Full-Year Financial Results

SANTA CLARA, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 3:40 p.m. Eastern Time.

Minerva Surgical to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Medical device company Minerva Surgical Inc (NASDAQ: UTRS) expects Q4 FY21 sales of $13.5 million - $13.7 million, versus $13.6 million posted a year ago and the consensus of $13.45 million. FY21 sales are expected to be $52.0 million - $52.2 million (prior view $51.0 million - $52.0 million), compared to $37.8 million in FY20 and the consensus of $51.75 million.

Minerva Surgical's Preliminary FY21 Revenues Top Expectations

SANTA CLARA, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a medical device company that has established a broad product line of commercially available, minimally invasive medical devices that address the most common causes of abnormal uterine bleeding (AUB) as alternatives to hysterectomy, today reported preliminary unaudited fourth quarter and full year 2021 revenue expectations.

Minerva Surgical Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

SANTA CLARA, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 11:15 a.m. Eastern Time.

Minerva Surgical to Present at the 40th Annual J.P. Morgan Healthcare Conference

SANTA CLARA, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner, today reported financial results for the third quarter ended September 30, 2021 and provided full-year 2021 revenue guidance.

Minerva Surgical, Inc. Third Quarter 2021 Financial Results

SANTA CLARA, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference on Wednesday, December 1st.

Minerva Surgical to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference

AUBandMe.com debuts at the American Association of Gynecologic Laparoscopists 50th Global Congress AUBandMe.com debuts at the American Association of Gynecologic Laparoscopists 50th Global Congress

Minerva Surgical Launches Educational Website for Women Living with Abnormal Uterine Bleeding

Minerva Surgical aims to transform uterine healthcare with its minimally invasive procedures. I like the potential of the business, and despite the current growth, I wonder if the competitive strength of the solutions is strong enough.

Minerva Surgical - Uterine Play For Sale

SANTA CLARA, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Minerva Surgical), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today announced the closing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $12.00 per share. The aggregate gross proceeds to Minerva Surgical from the offering were $75.0 million before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Minerva Surgical.

Minerva Surgical Announces Closing of Initial Public Offering

SANTA CLARA, Calif., Oct. 21, 2021 /PRNewswire/ -- Minerva Surgical, Inc. (Minerva Surgical), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $12.00 per share.

News for Minerva Surgical Stock (UTRS)